Addiction

Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX

Athena will employ its successful history of securing government contracts, spearheading such initiativesJACKSON CENTER, PA / ACCESSWIRE / January 9,…

2 years ago

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and…

2 years ago

Recovery Delivered Expands Services to Accept Medicaid in Ohio for Online Suboxone to Treat Opioid Addiction

Seeing a Suboxone doctor in Ohio just became much more affordable. Patients can now use their Ohio Medicaid to cover…

2 years ago

Clearview Treatment Programs Certified by PsychArmor as a ‘Veteran Ready’ Organization

BRENTWOOD, TN / ACCESSWIRE / January 4, 2024 / Odyssey Behavioral Healthcare, a leading provider of mental health, addiction, and…

2 years ago

Introducing PillSafe(R), the New ‘Smart’ Pill Bottle for Prescription Medication

PillSafe® protects the patient with a patented, innovative pill distribution control system that improves dosage safety, prevents prescription drug misuse,…

2 years ago

NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University

Scorpius subsidiary to manufacture novel biologic targeting substance use disorderDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE…

2 years ago

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and…

2 years ago

Corporate Governance at Alkermes

NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportBoard of DirectorsOur…

2 years ago

Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents…

2 years ago

Optimind Pharma Provides Corporate Update

TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider…

2 years ago